A pilot survey of attitudes and knowledge about opioid substitution therapy for HIV-infected prisoners.
A majority of inmates in the state of Connecticut Department of Corrections use opioids or are opioid dependent before incarceration. None of the state's prisons offer opioid substitution therapy other than for detoxification or maintenance therapy for women during pregnancy. On release to the community, most prisoners relapse to drug use and this has been associated with higher recidivism rates, and less adherence to antiretroviral medications for HIV-infected persons. Nationally and internationally, methadone (METH) and buprenorphine (BUP) have been found to decrease relapse to drug use, decrease recidivism rates, improve adherence to antiretroviral medications, decrease HIV-risk taking behaviors, and improve mortality. However, the general knowledge about opioid substitution therapy among correctionalfacility staff has been reported as substandard. This pilot study compiled results of answers to anonymous surveys from 27 individuals who work directly with inmates in a patient-care capacity for the Connecticut Department of Corrections (CT DOC) and CT DOC case-management referral program (Project TLC) in the year 2006. The surveys included questions regarding current attitudes and knowledge about opioid substitution therapy for prisoners. A minority of respondents refer released prisoners with a history of opioid dependency to METH or BUP treatment. The majority of correctional workers and case-management referral workers did not have knowledge about BUP or METH's ability to improve health and decrease HIV risk taking behaviors. This study found that more education of individuals treating and caring for HIV-infected opioid dependent prisoners is needed.
Springer
Sandra A
SA
Yale School of Medicine, New Haven, CT, USA.
Bruce
Robert D
RD
D001290:Attitude; D002047:Buprenorphine / Q000627:therapeutic use; D003416:Criminal Law; D015658:HIV Infections / Q000517:prevention & control*; D006801:Humans; D019359:Knowledge; D008691:Methadone / Q000627:therapeutic use; D009293:Opioid-Related Disorders / Q000188:drug therapy*; D010865:Pilot Projects; D011329:Prisoners
D002047:Buprenorphine; D008691:Methadone